Laseroptek Holds 26th Anniversary Ceremony... "Strengthening Disease Treatment Lineup"

Laseroptek held its 26th anniversary ceremony.

According to Laseroptek on July 27, starting from this anniversary, the company will accelerate the normalization of its business in the North American market and the expansion of its disease treatment laser portfolio. The company plans to ramp up its efforts to penetrate the global vascular laser market, spearheaded by its next-generation growth engine ‘VasQlar 589’. Moving beyond its current revenue structure focused on aesthetic dermatology equipment, Laseroptek aims to achieve a long-term revenue mix of 70% aesthetics and 30% disease treatment, thereby securing both profitability and sustainable growth.

Laseroptek has completed the establishment of a direct sales network focusing on the western United States and Texas, and has further reorganized its sales channels by expanding into the Canadian market. Based on this, the company expects a performance rebound from the second half of this year, and with the resolution of its U.S. litigation issue anticipated by the first quarter of next year, robust sales growth is expected to materialize first in the U.S. market, where prices are highest.

Juhong, Chairman of Laseroptek, said, "The reason we have been able to steadfastly focus on technology development for the past 26 years is thanks to the dedication of all our employees," and added, "As the industrial environment is rapidly changing, securing fundamentals and strengthening our foundation will be critical for survival and growth going forward."

Changjin Lee, CEO of Laseroptek, commented, "As the pace of change accelerates, technological prowess and organizational resilience become even more important." He continued, "We will expand our business scope from merely competing in the aesthetic equipment sector to covering disease treatment based on proprietary technology, and by targeting key global markets such as North America, we aim to become a global platform company encompassing both aesthetics and disease treatment."

This content was produced with the assistance of AI translation services.